Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Oncology in Clinical Practice
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2022 Professor Krzysztof Krzemieniecki Award

open access

Vol 14, No 6 (2018)
Review paper
View PDF Download PDF file
Get Citation

Malignant peripheral nerve sheath tumour (MPNST)

Anna M. Czarnecka12, Paweł Sobczuk13, Marcin Zdzienicki1, Mateusz Spałek4, Piotr Rutkowski1
DOI: 10.5603/OCP.2018.0050
·
Oncol Clin Pract 2018;14(6):364-376.
Affiliations
  1. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute — Oncology Centre, Warsaw, Poland
  2. Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
  3. Department of Experimental and Clinical Physiology, Warsaw Medical University, Warsaw, Poland
  4. Radiotherapy Department, Maria Sklodowska-Curie Institute — Oncology Centre, Warsaw, Poland

open access

Vol 14, No 6 (2018)
REVIEW ARTICLES

Abstract

MPNST is a malignant neoplasm of peripheral nerves, usually arising in connection with nerve trunks of the limbs and torso. It can develop de novo or on the basis of an already existing neurofibroma. Such tumours constitute about 5% of soft tissue sarcomas. In 90%, they occur in patients in the 2–5 decade of life. The main risk factor for this cancer is type 1 neurofibromatosis (von Recklinghausen disease). The radical surgical treatment — tumour excision, within the limits of healthy tissues (wide local excision), combined with adjuvant radiotherapy, is of primary importance in the treatment of MPNST. In cases of metastatic disease, palliative chemotherapy is used, using doxorubicin or doxorubicin with ifosfamide. Clinical improvement after chemotherapy is observed in approximately 25–30% of patients. Considering the development of molecular biology research of MPNST, one can hope for development of inhibitors that show greater effectiveness than typical chemotherapy in these patients in the near future. Currently, clinical trials with pembrolizumab, nivolumab in combination with ipilimumab, pexidartinib (KIT inhibitor, CSF1R and FLT3) in combination with sirolimus, sapanisertib (TORC 1/2 inhibitor) or LOXO-195 (inhibitor of neurotrophic tyrosine kinase inhibitors NTRK type 1, 2 and 3) are performed in MNSNT patients.

Abstract

MPNST is a malignant neoplasm of peripheral nerves, usually arising in connection with nerve trunks of the limbs and torso. It can develop de novo or on the basis of an already existing neurofibroma. Such tumours constitute about 5% of soft tissue sarcomas. In 90%, they occur in patients in the 2–5 decade of life. The main risk factor for this cancer is type 1 neurofibromatosis (von Recklinghausen disease). The radical surgical treatment — tumour excision, within the limits of healthy tissues (wide local excision), combined with adjuvant radiotherapy, is of primary importance in the treatment of MPNST. In cases of metastatic disease, palliative chemotherapy is used, using doxorubicin or doxorubicin with ifosfamide. Clinical improvement after chemotherapy is observed in approximately 25–30% of patients. Considering the development of molecular biology research of MPNST, one can hope for development of inhibitors that show greater effectiveness than typical chemotherapy in these patients in the near future. Currently, clinical trials with pembrolizumab, nivolumab in combination with ipilimumab, pexidartinib (KIT inhibitor, CSF1R and FLT3) in combination with sirolimus, sapanisertib (TORC 1/2 inhibitor) or LOXO-195 (inhibitor of neurotrophic tyrosine kinase inhibitors NTRK type 1, 2 and 3) are performed in MNSNT patients.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

malignant peripheral nerve sheath tumour; MPNST; Recklinghausen syndrome; NF1, sarcoma

About this article
Title

Malignant peripheral nerve sheath tumour (MPNST)

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 6 (2018)

Article type

Review paper

Pages

364-376

Page views

2792

Article views/downloads

2508

DOI

10.5603/OCP.2018.0050

Bibliographic record

Oncol Clin Pract 2018;14(6):364-376.

Keywords

malignant peripheral nerve sheath tumour
MPNST
Recklinghausen syndrome
NF1
sarcoma

Authors

Anna M. Czarnecka
Paweł Sobczuk
Marcin Zdzienicki
Mateusz Spałek
Piotr Rutkowski

References (92)
  1. Hirbe A, Gutmann D. The management of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: challenges, progress, and future prospects. Expert Opinion on Orphan Drugs. 2017; 5(8): 623–631.
    CrossRef
  2. Pala-Sadza A, Zajączkiewicz H, Banaś-Samson R, et al. Rzadki przypadek złośliwego nerwiaka osłonkowego jamy nosa. PPOTOR. 2014; 3(4): 210–213.
    CrossRef
  3. Boczej R, Walas R, Motyka M. Olbrzymi guz złośliwy nerwów obwodowych. Chirurgia Polska. 2013; 15(2): 141–145.
  4. De Raedt T, Brems H, Wolkenstein P, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003; 72(5): 1288–1292.
    CrossRefPubMed
  5. Evans D. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002; 39(5): 311–314.
    CrossRef
  6. Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014; 19(2): 193–201.
    CrossRefPubMed
  7. Shurell E, Tran LM, Nakashima J, et al. Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients. BMC Cancer. 2014; 14: 827.
    CrossRefPubMed
  8. Jadayel D, Fain P, Upadhyaya M, et al. Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature. 1990; 343(6258): 558–559.
    CrossRefPubMed
  9. Kahen EJ, Brohl A, Yu D, et al. Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget. 2018; 9(32): 22571–22585.
    CrossRefPubMed
  10. Endo M, Yamamoto H, Setsu N, et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013; 19(2): 450–461.
    CrossRefPubMed
  11. Brohl AS, Kahen E, Yoder SJ, et al. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep. 2017; 7(1): 14992.
    CrossRefPubMed
  12. Zou CY, Smith KD, Zhu QS, et al. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009; 8(5): 1157–1168.
    CrossRefPubMed
  13. Adnane L, Trail P, Taylor I, et al. Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature. Methods in Enzymology. 2006; 407: 597–612.
    CrossRef
  14. Gudena V, Verma N, Post G, et al. Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. Cancer Biol Ther. 2014; 7(6): 810–813.
    CrossRef
  15. D'Adamo DR, Keohan ML, Carvajal RD, et al. A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST). J Clin Oncol. 2011; 29(Suppl 15): 10025.
    CrossRef
  16. Peacock JD, Cherba D, Kampfschulte K, et al. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. J Transl Med. 2013; 11: 213.
    CrossRefPubMed
  17. Brosius SN, Roth KA, Carroll SL. Combinatorial treatment of malignant peripheral nerve sheath tumors with tyrosine kinase inhibitors hinders proliferation and survival. The FASEB Journal. 2013; 27(Suppl 1).
  18. Torres KE, Zhu QS, Bill K, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011; 17(12): 3943–3955.
    CrossRefPubMed
  19. Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013; 123(1): 340–347.
    CrossRefPubMed
  20. Fischer-Huchzermeyer S, Dombrowski A, Wilke G, et al. MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro. PLoS One. 2017; 12(11): e0187700.
    CrossRefPubMed
  21. Wu J, et al. EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene. 2014; 33(2): 173–80.
    CrossRef
  22. Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell. 2008; 135(3): 437–448.
    CrossRefPubMed
  23. Brekke HR, Ribeiro FR, Kolberg M, et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol. 2010; 28(9): 1573–1582.
    CrossRefPubMed
  24. Yang J, Du X. Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy. Surg Oncol. 2013; 22(3): e53–e57.
    CrossRefPubMed
  25. Beert E, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Gene Chromosome Canc. 2011; 50(12): 1021–1032.
    CrossRef
  26. Thomas LE, Winston J, Rad E, et al. Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours. Hum Genomics. 2015; 9(1): 3.
    CrossRefPubMed
  27. Subramanian S, Thayanithy V, West RB, et al. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol. 2010; 220(1): 58–70.
    CrossRefPubMed
  28. Feber A, Wilson GA, Zhang Lu, et al. Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res. 2011; 21(4): 515–524.
    CrossRefPubMed
  29. Presneau N, Eskandarpour M, Shemais T, et al. MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. Br J Cancer. 2013; 108(4): 964–972.
    CrossRefPubMed
  30. Röhrich M, Koelsche C, Schrimpf D, et al. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 2016; 131(6): 877–887.
    CrossRefPubMed
  31. Cassier PA, Lefranc A, Amela EY, et al. A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer. 2013; 109(4): 909–914.
    CrossRefPubMed
  32. Seno N, Fukushima T, Gomi D, et al. Successful treatment with doxorubicin and ifosfamide for mediastinal malignant peripheral nerve sheath tumor with loss of H3K27me3 expression. Thorac Cancer. 2017; 8(6): 720–723.
    CrossRefPubMed
  33. Skotheim RI, Kallioniemi A, Bjerkhagen B, et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol. 2003; 21(24): 4586–4591.
    CrossRefPubMed
  34. Amirnasr A, Verdijk RM, van Kuijk PF, et al. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. PLoS One. 2017; 12(8): e0183155.
    CrossRefPubMed
  35. Fukushima S, Endo M, Matsumoto Y, et al. Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. PLoS ONE. 2017; 12(5): e0178064.
    CrossRef
  36. Shurell E, Singh AS, Crompton JG, et al. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. Oncotarget. 2016; 7(39): 64300–64308.
    CrossRefPubMed
  37. Lehnhardt M, Daigeler A, Homann HH, et al. Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases. Chirurg. 2009; 80(4): 341–347.
    CrossRefPubMed
  38. Sandrucci S, Trama A, Quagliuolo V, et al. Accreditation for centers of sarcoma surgery. Updates Surg. 2017; 69(1): 1–7.
    CrossRefPubMed
  39. Le Guellec S, Decouvelaere AV, Filleron T, et al. Malignant Peripheral Nerve Sheath Tumor Is a Challenging Diagnosis: A Systematic Pathology Review, Immunohistochemistry, and Molecular Analysis in 160 Patients From the French Sarcoma Group Database. Am J Surg Pathol. 2016; 40(7): 896–908.
    CrossRefPubMed
  40. Rodriguez FJ, Folpe AL, Giannini C, et al. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012; 123(3): 295–319.
    CrossRefPubMed
  41. Kim A, Stewart DR, Reilly KM, et al. Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies. Sarcoma. 2017; 2017: 1–10.
    CrossRefPubMed
  42. Zhou H, Coffin CM, Perkins SL, et al. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am J Surg Pathol. 2003; 27(10): 1337–1345.
    PubMed
  43. Kamran SC, Howard SA, Shinagare AB, et al. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location. Eur J Surg Oncol. 2013; 39(1): 46–52.
    CrossRefPubMed
  44. Mito J, Qian X, Doyle L, et al. Role of Histone H3K27 Trimethylation Loss as a Marker for Malignant Peripheral Nerve Sheath Tumor in Fine-Needle Aspiration and Small Biopsy Specimens. Am J Clin Pathol. 2017; 148(2): 179–189.
    CrossRefPubMed
  45. Wakely PE, Ali SZ, Bishop JA. The cytopathology of malignant peripheral nerve sheath tumor: a report of 55 fine-needle aspiration cases. Cancer Cytopathol. 2012; 120(5): 334–341.
    CrossRefPubMed
  46. Tonsgard JH. Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol. 2006; 13(1): 2–7.
    CrossRefPubMed
  47. Mautner VF, Asuagbor FA, Dombi E, et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol. 2008; 10(4): 593–598.
    CrossRefPubMed
  48. Derlin T, Tornquist K, Münster S, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2013; 38(1): e19–e25.
    CrossRefPubMed
  49. Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008; 19(2): 390–394.
    CrossRefPubMed
  50. Salamon J, Veldhoen S, Apostolova I, et al. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol. 2014; 24(2): 405–412.
    CrossRefPubMed
  51. Chirindel A, Chaudhry M, Blakeley JO, et al. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization. J Nucl Med. 2015; 56(3): 379–385.
    CrossRefPubMed
  52. Krzakowski M. Zalecenia w zakresie zastosowania badań pozytonowej emisyjnej tomografii w onkologii. Zalecenia w zakresie zastosowania badań pozytonowej emisyjnej tomografii w onkologii. PTO Nowotwory. 2011; 61(1): 57–69.
  53. Tovmassian D, Abdul Razak M, London K. The Role of [F]FDG-PET/CT in Predicting Malignant Transformation of Plexiform Neurofibromas in Neurofibromatosis-1. Int J Surg Oncol. 2016; 2016: 1–7.
    CrossRefPubMed
  54. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007; 44(2): 81–88.
    CrossRefPubMed
  55. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23(Suppl 7): vii92–vii99.
    CrossRefPubMed
  56. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005; 23(33): 8422–8430.
    CrossRefPubMed
  57. Higham CS, Steinberg SM, Dombi E, et al. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017; 2017: 1–8.
    CrossRefPubMed
  58. Gronchi A, Stacchiotti S, Verderio P, et al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann Oncol. 2016; 27(12): 2283–2288.
    CrossRefPubMed
  59. Hirbe AC, Cosper PF, Dahiya S, et al. Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017; 2017: 1–6.
    CrossRefPubMed
  60. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017; 18(6): 812–822.
    CrossRefPubMed
  61. Karpinsky G, Krawczyk MA, Izycka-Swieszewska E, et al. Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. J Cancer Res Clin Oncol. 2018; 144(3): 519–529.
    CrossRefPubMed
  62. Gupta G, Mammis A, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am. 2008; 19(4): 533–543, v.
    CrossRefPubMed
  63. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008; 113(3): 573–581.
    CrossRefPubMed
  64. Anghileri M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006; 107(5): 1065–1074.
    CrossRef
  65. Wong WW, Hirose T, Scheithauer BW, et al. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998; 42(2): 351–360.
    CrossRef
  66. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014; 110(2): 115–122.
    CrossRefPubMed
  67. Jensen AD, Uhl M, Chaudhri N, et al. Carbon Ion irradiation in the treatment of grossly incomplete or unresectable malignant peripheral nerve sheaths tumors: acute toxicity and preliminary outcome. Radiat Oncol. 2015; 10: 109.
    CrossRefPubMed
  68. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009; 249(6): 1014–1022.
    CrossRefPubMed
  69. Kolberg M, Høland M, Agesen TH, et al. Survival meta-analyses for > 1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. 2013; 15(2): 135–147.
    CrossRefPubMed
  70. Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016; 56: 77–84.
    CrossRefPubMed
  71. Hwang InK, Hahn SM, Kim HS, et al. Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1. Cancer Res Treat. 2017; 49(3): 717–726.
    CrossRefPubMed
  72. Longhi A, Errani C, Magagnoli G, et al. High grade malignant peripheral nerve sheath tumors: outcome of 62 patients with localized disease and review of the literature. J Chemother. 2010; 22(6): 413–418.
    CrossRefPubMed
  73. Bishop AJ, Zagars GK, Torres KE, et al. Malignant Peripheral Nerve Sheath Tumors:A Single Institution's Experience Using Combined Surgery and Radiation Therapy. Am J Clin Oncol. 2018; 41(5): 465–470.
    CrossRef
  74. Stucky CCH, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012; 19(3): 878–885.
    CrossRefPubMed
  75. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol. 2011; 22(1): 207–214.
    CrossRefPubMed
  76. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13(7): 1537–1545.
    CrossRefPubMed
  77. Judson I, Verweij J, Gelderblom H, et al. European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014; 15(4): 415–423.
    CrossRefPubMed
  78. Zehou O, Fabre E, Zelek L, et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis. 2013; 8(1): 127.
    CrossRefPubMed
  79. Torres KE, Liu J, Young E, et al. Expression of 'drugable' tyrosine kinase receptors in malignant peripheral nerve sheath tumour: potential molecular therapeutic targets for a chemoresistant cancer. Histopathology. 2011; 59(1): 156–159.
    CrossRefPubMed
  80. Tawbi H, Thomas D, Lucas DR, et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist. 2008; 13(4): 459–466.
    CrossRefPubMed
  81. Albritton KH, Rankin C, Coffin CM, et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). JCO. 2006; 24(Suppl 18): 9518–9518.
    CrossRef
  82. Widemann B, Meyer C, Cote G, et al. SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). JCO. 2016; 34(Suppl 15): 11053.
    CrossRef
  83. AeRang K, Reinke DK, Cichowski K, et al. SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST). JCO. 2014; 32(Suppl 15): TPS10603–TPS10603.
    CrossRef
  84. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. JCO. 2009; 27(19): 3148–3153.
    CrossRefPubMed
  85. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. JCO. 2009; 27(19): 3133–3140.
    CrossRefPubMed
  86. Yoo KH, Kim HS, Lee SuJ, et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer. 2015; 15(1): 154.
    CrossRefPubMed
  87. Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016; 122(9): 1408–1416.
    CrossRefPubMed
  88. Manji G, Patwardhan P, Lee S, et al. Phase 1/2 study of combination therapy with pexidartinib and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors. JCO. 2016; 34(Suppl 15): TPS11070–TPS11070.
    CrossRef
  89. LaFemina J, Qin LX, Moraco NH, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol. 2013; 20(1): 66–72.
    CrossRefPubMed
  90. Porter DE, Prasad V, Foster L, et al. Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma. 2009; 2009: 756395.
    CrossRefPubMed
  91. Malbari F, Spira M, B Knight P, et al. Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis: Impact of Family History. J Pediatr Hematol Oncol. 2018; 40(6): e359–e363.
    CrossRefPubMed
  92. Widemann BC, Italiano A. Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. JCO. 2018; 36(2): 160–167.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl